The estimation of tumor cell percentage for molecular testing by pathologists is not accurate
- 1 February 2014
- journal article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 27 (2), 168-174
- https://doi.org/10.1038/modpathol.2013.134
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working groupLung Cancer, 2011
- Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004